fbpx
  1. Biogen’s stock could fall 10% on new Alzheimer’s drug data this week, top analyst says  CNBC
  2. Analyst: Biogen’s aducanumab is not getting approved absent a deus ex machina  FierceBiotech
  3. Biogen Stock: Why Alzheimer’s Treatment Data Could Rock The Biogen Company  Investor’s Business Daily
  4. Biogen’s Alzheimer’s Drug Won’t Get Approved, Analyst Says  Barron’s
  5. Top Biogen scientist explains why he’s confident in aducanumab  STAT
  6. View full coverage on Google News